The consanguinity effect on QF-PCR diagnosis of autosomal anomalies

2006 ◽  
Vol 26 (5) ◽  
pp. 409-414 ◽  
Author(s):  
Michel B. Choueiri ◽  
Nadine J. Makhoul ◽  
Tony G. Zreik ◽  
Farid Mattar ◽  
Abdallah M. Adra ◽  
...  
Keyword(s):  
Pcr Diagnosis

Identification of a novel CBFB-MYH11 transcript: implications for RT–PCR diagnosis

2001 ◽  
Vol 2 (3) ◽  
pp. 206-209 ◽  
Author(s):  
Bert A Van der Reijden ◽  
Linda de Wit ◽  
Sonja van der Poel ◽  
Erna B Luiten ◽  
Marina Lafage-Pochitaloff ◽  
...  
Keyword(s):  
Rt Pcr ◽  
Pcr Diagnosis

scholarly journals P052 Leflunomide and severe COVID-19 outcome: a cautionary observation from the COVID-19 Scottish Registry of Autoimmune Rheumatic Diseases (SCAR-19)

Rheumatology ◽  
2021 ◽  
Vol 60 (Supplement_1) ◽  
Author(s):  
Maira Karabayas ◽  
James Brock ◽  
Gillian Fordyce ◽  
Neil Basu
Keyword(s):  
Rheumatic Diseases ◽  
Clinical Characteristics ◽  
National Registry ◽  
Favourable Outcome ◽  
Non Invasive ◽  
Autoimmune Rheumatic Diseases ◽  
Non Invasive Ventilation ◽  
Pcr Diagnosis ◽  
Related Symptom ◽  
Disease Modifying

Abstract Background/Aims  Leflunomide, a conventional disease modifying drug (csDMARD), is used in a variety of autoimmune rheumatic diseases (ARD) due to its immunomodulating, immunosuppressive and antiproliferative properties. This agent does however confer a greater infection risk and, due to its long half-life, drug washout procedures are often advised in the context of serious infections. Interestingly, Leflunomide is currently being tested as a potential therapy for COVID-19 in the general population. It is unknown whether leflunomide therapy is associated with a poor or favourable outcome among ARD patients infected with COVID-19. Methods  A Scottish-wide registry was rapidly developed in March 2020. Clinical characteristics and outcomes of infected cases were collated across all Scottish health boards. Eligible patients included any adult leflunomide treated ARD patients with a confirmed (clinically or PCR) diagnosis of COVID-19. Results  Of the 69 cases included in the registry, n = 4 were treated with leflunomide (75% female; mean age 61, SD 4.2). N = 2 were treated with combination baricitinib or hydroxychloroquine respectively, whilst n = 1 received recent corticosteroid therapy (intramuscular Kenalog). Comorbidities observed in this sub-cohort include diabetes mellitus n = 3, hypertension n = 2, cardiovascular disease n = 1, lung disease n = 1 and latent TB n = 1. At presentation, all patients (n = 4) experienced the established COVID-19 related symptom triad of dyspnoea, cough and fever and promptly developed acute respiratory syndrome. Diarrhoea was also recorded in n = 2 and constitutional upset n = 3. All patients suffered a serious COVID-19 disease outcome (defined as a requirement of invasive or non-invasive ventilation (n = 4) and/ or death (n = 2). P052 Table 1:Patient demographics, clinical characteristics and outcomesPatient 1Patient 2Patient 3Patient 4Age58635766SexFemaleFemaleMaleFemaleRheumatic diagnosisRheumatoid arthritisPsoriatic arthritisPsoriatic arthritisRheumatoid ArthritisComorbiditiesDiabetesHypertension Diabetes COPDNilIschaemic heart disease Hypertension Diabetes Latent TBClinical presentationDyspnoea Cough Fever Confusion Constitutional upsetDyspnoea Cough Fever Diarrhoea Constitutional upsetDyspnoea Cough Fever Constitutional upsetDyspnoea Cough Fever Diarrhoea Constitutional upsetAdditional csDMARD*NilNilNilHydroxychloroquinebDMARD**/ tsDMARD***BaricitinibNilNilNilSteroid therapyNilNilNilIM KenalogInvasive or non-invasive ventilationYesYesYesYesDeathNoNoYesYes* conventional disease modifying drug,**biologic disease modifying drug,***targeted synthetic disease modifying drug. Conclusion  Preliminary data from this Scotland-wide registry has identified only a small number of leflunomide treated ARD patients infected with COVID-19. However, it is concerning that all cases experienced a serious outcome. Given the relatively infrequent prescription of this drug, combining similar national registry data is necessary to ensure this observation is not spurious. If confirmed, leflunomide washout procedures should be encouraged among such patients when they first present with COVID-19. Disclosure  M. Karabayas: None. J. Brock: None. G. Fordyce: None. N. Basu: None.

scholarly journals PCR Diagnosis of Some Citrus Viroids in Field Samples

1996 ◽  
Vol 13 (13) ◽  
Author(s):  
M. Tessitori ◽  
R. La Rosa ◽  
G. Albanese ◽  
A. Catara
Keyword(s):  
Pcr Diagnosis ◽  
Field Samples ◽  
Citrus Viroids

scholarly journals PCR diagnosis of infectious diseases

2017 ◽  
Vol 63 (7-8) ◽  
pp. 472-474
Author(s):  
Tomáš Freiberger
Keyword(s):  
Infectious Diseases ◽  
Pcr Diagnosis

scholarly journals Chagas Disease in Pregnant Women from Endemic Regions Attending the Hospital General de Mexico, Mexico City

2022 ◽  
Vol 7 (1) ◽  
pp. 8
Author(s):  
Indira Chakravarti ◽  
Monica Miranda-Schaeubinger ◽  
Adriana Ruiz-Remigio ◽  
Carlos Briones-Garduño ◽  
Edith A. Fernández-Figueroa ◽  
...  
Keyword(s):  
Pregnant Women ◽  
Mexico City ◽  
Chagas Disease ◽  
Care Management ◽  
Public Health Importance ◽  
Molecular Tests ◽  
Pcr Diagnosis ◽  
Significant Public Health ◽  
Hospital General ◽  
Cruzi Infection

Trypanosoma cruzi infection leads to Chagas disease (CD), a neglected tropical infection of significant public health importance in South and Central America and other, non-endemic, countries. Pregnant women and their children are of particular importance to screen as T. cruzi can be transmitted vertically. The objective of this study was to screen for T. cruzi infection among pregnant women from endemic areas seen at the Hospital General de Mexico for prenatal care, so that they and their children may be quickly connected to CD treatment. Pregnant women were recruited through the hospital prenatal clinic and screened for T. cruzi infection using a series of serological and molecular tests. Of 150 screened patients, mean age 26.8 (SD 6.4), 30 (20.0%) were positive by at least one diagnostic test. Of these, only nine (6%) were positive as determined by PCR. Diagnosis of chronic CD is difficult in endemic places like Mexico due to the limitations of current commercially available diagnostic tests. Further evaluation of diagnostic performance of various assays could improve current CD diagnostic algorithms and proper care management in these regions. Genetic variability in the parasite may also play a role in the differing assay performances seen in this study, and this may be a valuable avenue of further research.

scholarly journals Zika Virus Serologic Diagnosis by NS1 ELISA in Curacao

2017 ◽  
Vol 4 (suppl_1) ◽  
pp. S302-S303 ◽  
Author(s):  
Samantha Manuel ◽  
Liane Virginia-Cova ◽  
Loubiela Joseph ◽  
Chris Roggeveen ◽  
Radjin Steingrover
Keyword(s):  
Zika Virus ◽  
Cross Reactivity ◽  
Pregnant Female ◽  
Serum Samples ◽  
Zikv Infection ◽  
Igm Elisa ◽  
Pcr Diagnosis ◽  
Two Samples ◽  
Negative Controls

Abstract Background Zika virus (ZIKV) was introduced in the Caribbean island of Curacao in January 2016. A commercially available ZIKV IgM and IgG ELISA was evaluated on patients that were PCR-positive for ZIKV. Methods ZIKV infection was established by PCR in urine samples. Samples from PCR-positive patients were selected for validation of a ZIKV NS1 IgG and IgM ELISA. Patients with a follow-up sample ≥ 2 weeks after initial presentation were used to assess the sensitivity of the assay. Samples of 15 historical controls with serological evidence of Dengue, Chikungunya or an unrelated viral infection were included to establish specificity and cross-reactivity. Results Fourteen patients with positive ZIKV PCR diagnosis had repeated serum samples drawn ≥ 2 weeks after the initial sample. The combined results of these repeated IgM and IgG tests resulted in a sensitivity of 92%. One pregnant female showed no presence of IgG or IgM in any of the two samples. Testing of the panel of historical ZIKV-negative controls resulted in a specificity of 100% in both the quantitative and semi-quantitative setting of the ELISA. One patient with known high-titers of antibodies against Chikungunya virus in the respective panel displayed borderline reactive results for ZIKV IgG in both quantitative and semi-quantitative setting of the assay. Conclusion In this PCR-positive ZIKV cohort of patients, the newly available ZIKV NS1 ELISA displayed excellent performance characteristics. Cross-reactivity was indicated for Chikungunya in one case. No cross-reactivity was found for Dengue virus infection. One pregnant female showed no signs of developing anti-ZIKV IgM or IgG in this study. In the light of intrauterine pathogenesis, the lack of development of maternal IgG during ZIKV infection is a concern. Disclosures All authors: No reported disclosures.

Armoured exogenous internal control for real-time PCR diagnosis of avian influenza

2019 ◽  
Vol 48 (5) ◽  
pp. 492-498
Author(s):  
D. B. Andreychuk ◽  
A. V. Andriyasov ◽  
Z. B. Nikonova ◽  
А. А. Kozlov ◽  
D. L. Suarez ◽  
...  
Keyword(s):  
Avian Influenza ◽  
Real Time ◽  
Internal Control ◽  
Real Time Pcr ◽  
Pcr Diagnosis ◽  
Exogenous Internal Control
Sign in / Sign up

Export Citation Format

Share Document